ReviewJournal of neuro-oncology1994
Drug resistance in brain tumors.
Review in Journal of neuro-oncology, 1994. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 65 citations in OpenAlex.
- A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse.British journal of cancer · 2000Trial
- Phase II trial of cystemustine, a new nitrosourea, as treatment of high-grade brain tumors in adults.Journal of neuro-oncology · 2000Trial
- Development and Characterization of Methylene Blue Oleate Salt-Loaded Polymeric Nanoparticles and their Potential Application as a Treatment for Glioblastoma.Journal of nanomedicine & nanotechnology · 2017Article
- The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors.Frontiers in immunology · 2017Article
- CD133 and DNA-PK regulate MDR1 via the PI3K- or Akt-NF-κB pathway in multidrug-resistant glioblastoma cells in vitro.Oncogene · 2016Article
- A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.BMC cancer · 2015Article
- Cellular immunotherapy for pediatric solid tumors.Cytotherapy · 2015Review
- Glutamate transporters in the biology of malignant gliomas.Cellular and molecular life sciences : CMLS · 2014Review
- Glioma residual or recurrence versus radiation necrosis: accuracy of pentavalent technetium-99m-dimercaptosuccinic acid [Tc-99m (V) DMSA] brain SPECT compared to proton magnetic resonance spectroscopy (1H-MRS): initial results.Journal of neuro-oncology · 2012Article
- Identification of chemosensitivity nodes for vinblastine through small interfering RNA high-throughput screens.The Journal of pharmacology and experimental therapeutics · 2011Article
- Myc down-regulation affects cyclin D1/cdk4 activity and induces apoptosis via Smac/Diablo pathway in an astrocytoma cell line.Cell proliferation · 2009Article
- Immunohistochemical markers for prognosis of cerebral glioblastomas.Journal of neuro-oncology · 2002Article
- Antitumor efficacy of SarCNU in a human glioma xenograft model expressing both MGMT and extraneuronal monoamine transporter.Journal of neuro-oncology · 2001Article
- Prognostic value of immunoexpression of the chemoresistance-related proteins in ependymomas: an analysis of 76 cases.Journal of neuro-oncology · 1999Article
- Expression of multidrug resistance protein gene in patients with glioma after chemotherapy.Journal of neuro-oncology · 1998Article
- Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases.Proceedings of the National Academy of Sciences of the United States of America · 1998Article
- Drug resistance and apoptosis in ENU-induced rat brain tumors treated with anti-cancer drugs.Journal of neuro-oncology · 1998Article
- Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines.Journal of neuro-oncology · 1996Article
- Genomic copy number changes of DNA repair genes ERCC1 and ERCC2 in human gliomas.Journal of neuro-oncology · 1995Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resistance to chemotherapy in brain tumors is complex and may involve multiple mechanisms. For commonly used drugs, such as nitrosoureas and platinum compounds, major mechanisms may involve increaded DNA repair or removal of the drug-DNA adducts. For water soluble nitrosoureas and also for platinum compounds, other mechanisms, such as alteration in drug transport, may be important. Another major mechanism may involve glutathione and glutathione-S-transferase pathways. For vinca alkaloids and epipodophyllotoxins p-glycoprotein mediated MDR appears to be the major feature in drug resistance. In addition, alteration of tubulin and topoisomerase II have been described in resistance to vinca alkaloids and epipodophyllotoxins respectively. Recently, increased multidrug resistance associated protein gene expression has been found in glioma cells and brain tumor samples; its clinical significance requires further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.